$GTHX News
Last published 2y ago
- 2y agoONCYGTHXSNYHALOGlobal Cancer Rates Surge as Biotech Innovators Work on New TherapiesPR NewswireUSA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase ...
- 2y agoGTHXPharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferGlobeNewswire- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK,
- 2y agoGTHXPharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting PeriodGlobeNewswireHOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron
- 2y agoBAYARCFAOBDCGTHXKuehn Law Encourages BAYA, RCFA, OBDC, and GTHX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoGTHXG1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsGlobeNewswire- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - -
- 2y agoGTHXPharmacosmos Group to Acquire G1 TherapeuticsGlobeNewswire- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300
- 2y agoGTHXG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
- 2y agoGTHXG1 Therapeutics Added to the Russell 2000® and 3000® IndexesGlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell
- 2y agoGTHXG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)GlobeNewswire- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,650
- 2y agoGTHXMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)GlobeNewswire- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data
- 2y agoGTHXG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingGlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of
- 2y agoGTHXG1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation SummitGlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Medical Officer Dr. Raj Malik and Chief
- 2y agoGTHXG1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesGlobeNewswireRESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100
- 2y agoGTHXG1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoGTHXG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsGlobeNewswire- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results
- 2y agoGTHXG1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibGlobeNewswireRESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug discovery and
- 2y agoGTHXG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024GlobeNewswireRESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
- 2y agoONCYGILDGTHXAZN+1Biotech Innovations Paving the Way in Breast Cancer FightPR NewswireUSA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which...
- 2y agoGTHXG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100
- 2y agoGTHXG1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsGlobeNewswire- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA
- 2y agoGTHXG1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate
- 2y agoGTHXG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
- 2y agoGTHXG1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended
- 2y agoGTHXG1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for Patients Receiving
- 2y agoGTHXG1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300
- 2y agoGTHXG1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer TherapyGlobeNewswire- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival
- 2y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,700
- 2y agoGTHXG1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib
- 3y agoGTHXG1 Therapeutics, Inc. (GTHX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoGTHXG1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational HighlightsGlobeNewswire- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter - - Confirmed Expectation of Interim Overall Survival (OS) Analysis
- 3y agoGTHXReal World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world
- 3y agoGTHXG1 Therapeutics' COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a
- 3y agoGTHXG1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
- 3y agoGTHXG1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care SymposiumGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster
- 3y agoBDTXGTHXBlack Diamond Therapeutics Announces CEO TransitionGlobeNewswireCurrent Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage
- 3y agoGTHXG1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Roberts will provide a
- 3y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800
- 3y agoGTHXG1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational HighlightsGlobeNewswire- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic
- 3y agoGTHXG1 Therapeutics to Participate in Two August Investor ConferencesGlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences. On
- 3y agoGTHXNew Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)GlobeNewswire- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed Consistently Lower
- 3y agoGTHXG1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
- 3y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 5,600
- 3y agoGTHXTrilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and EfficacyGlobeNewswire- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T Cells - -
- 3y agoGTHXG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300